Visudyne Injection, Powder, Lyophilized, For Solution
NDC Package 0187-5600-15

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. NDC HCPCS Crosswalk
    3. Frequently Asked Questions

Package Information

Visudyne (verteporfin for injection) injection is verteporfin is used along with laser light treatment to treat certain serious eye conditions (e.g., macular degeneration, pathologic myopia, ocular histoplasmosis). This formulation utilizes a injection, powder, lyophilized, for solution delivery system. Marketed by Bausch Health Us Llc, this product is identified by NDC 0187-5600 and is authorized under FDA application NDA021119.

Identification & Billing

NDC Package Code
0187-5600-15
Package Description
1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 CARTON
Product Code
0187-5600
11-Digit Billing Format
00187560015
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Visudyne
Non-Proprietary Name
Verteporfin For Injection
Substance Name
Verteporfin
Dosage Form
Injection, Powder, Lyophilized, For Solution - A dosage form intended for the solution prepared by lyophilization ("freeze drying"), a process which involves the removal of water from products in the frozen state at extremely low pressures; this is intended for subsequent addition of liquid to create a solution that conforms in all respects to the requirements for Injections.
Administration Route
Intravenous - Administration within or into a vein or veins.
Active Ingredient(s)
VERTEPORFIN 15 mg/1
Pharmacologic Class
Usage Information
Verteporfin is used along with laser light treatment to treat certain serious eye conditions (e.g., macular degeneration, pathologic myopia, ocular histoplasmosis). It is used to help prevent decreased vision and blindness. After you have received the injection of verteporfin, your doctor will use laser light treatment on the affected eye(s). The laser light will change the drug to a form that works by damaging only those cells that cause the serious eye problem.

Regulatory & Marketing

Labeler Name
Bausch Health Us Llc
Product Type
Human Prescription Drug
FDA Application #
NDA021119
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
04-12-2000
End Marketing Date
12-01-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Billing & HCPCS Mapping

To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.

J3396
Source: ASP
Verteporfin injection
HCPCS Dosage 0.1 MG
Units / Pkg 150

Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0187-5600-15 identifies a specific commercial package of 1 injection, powder, lyophilized, for solution in 1 carton of Visudyne, a human prescription drug labeled by Bausch Health Us Llc. This injection, powder, lyophilized, for solution is formulated for intravenous use and contains verteporfin as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Bausch Health Us Llc on April 12, 2000.

What are the primary indications for this medication?

Verteporfin is used along with laser light treatment to treat certain serious eye conditions (e.g., macular degeneration, pathologic myopia, ocular histoplasmosis). It is used to help prevent decreased vision and blindness. After you have received the injection of verteporfin, your doctor will use laser light treatment on the affected eye(s). The laser light will change the drug to a form that works by damaging only those cells that cause the serious eye problem.

How is this Bausch Health Us Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00187560015. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0187-5600-15
11-Digit CMS (5-4-2)
00187-5600-15

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.